NCT02632708Active, not recruitingPhase 1
A Phase 1 study to test the safety of an oral investigational drug (either AG-120 or AG-221) in combination with standard chemotherapeutic treatment for patients newly diagnosed with a blood malignancy (AML) with an IDH1 mutation and/or IDH2 mutation
Source: EU CTIS (euclinicaltrials.eu) · Last updated 12 Oct 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (estimated)
- First submitted
- 5 Sept 2024
- Start date
- 16 Dec 2015
- Lead sponsor
- Institut De Recherches Internationales Servier IRIS
- NCT number
- NCT02632708
- EU CT number
- 2024-511380-29-00
- EudraCT number
- 2015-004290-33
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 2
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stichting Amsterdam UMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.